zenagamtide B 10176
Sponsors
Novo Nordisk A/S
Conditions
Participants with type 2 diabetesParticipants with type 2 diabetes and chronic kidney diseaseType 2 diabetes (T2D) and increased cardiovascular (CV) risk not in adequate glycaemic control on 1–3 marketed oral glucose lowering medications.
Phase 3
Efficacy and safety of zenagamtide s.c. once weekly compared to insulin glargine s.c. once daily in participants with type 2 diabetes and increased cardiovascular risk inadequately controlled on 1–3 oral glucose-lowering medications (AMBITION 7)
WithdrawnCTIS2026-525209-11-00
Target: 110Updated: 2026-09-04
Efficacy and safety of zenagamtide s.c. once weekly compared to semaglutide s.c. once weekly at higher dose levels in participants with type 2 diabetes inadequately controlled on metformin, SGLT2i, or both (AMBITION 3)
Not yet recruitingCTIS2026-525472-26-00
Target: 220Updated: 2026-10-23
Efficacy and safety of zenagamtide s.c. once weekly compared to placebo in participants with type 2 diabetes inadequately controlled on diet and exercise (AMBITION 1)
Not yet recruitingCTIS2026-525470-18-00
Target: 35Updated: 2026-10-26
Efficacy and safety of zenagamtide s.c. once weekly compared to placebo in participants with type 2 diabetes and chronic kidney disease inadequately controlled on once daily basal insulin alone or in combination with metformin, SGLT2i, or both (AMBITION 2)
Not yet recruitingCTIS2026-525471-13-00
Target: 95Updated: 2026-10-28